F9 and hemophilia B: However, approximately 5% of adult patients with hemophilia B develop inhibitory antibodies against recombinant forms of FIX [76], highlighting the need for the development of universal gene therapy strategies using CRISPR-Cas editing of F9, employing non-viral delivery systems [77].